Curis FY2025 EPS Estimate Reduced by Cantor Fitzgerald

Curis, Inc. (NASDAQ:CRIS) – Analysts at Cantor Fitzgerald decreased their FY2025 earnings per share (EPS) estimates for shares of Curis in a research report issued on Wednesday, May 7th. Cantor Fitzgerald analyst L. Watsek now anticipates that the biotechnology company will post earnings per share of ($3.01) for the year, down from their prior estimate of ($1.52). The consensus estimate for Curis’ current full-year earnings is ($7.12) per share.

Curis (NASDAQ:CRIS) last announced its quarterly earnings results on Tuesday, May 6th. The biotechnology company reported ($1.25) EPS for the quarter, missing analysts’ consensus estimates of ($1.14) by ($0.11). The business had revenue of $2.38 million during the quarter, compared to analysts’ expectations of $2.37 million. Curis had a negative return on equity of 923.37% and a negative net margin of 443.35%. During the same period in the previous year, the business earned ($2.05) EPS.

Several other analysts have also recently weighed in on the company. HC Wainwright cut their price objective on Curis from $20.00 to $16.00 and set a “buy” rating on the stock in a research report on Monday, March 31st. StockNews.com assumed coverage on shares of Curis in a research note on Thursday. They set a “hold” rating for the company.

Curis Trading Down 10.0 %

NASDAQ:CRIS opened at $1.89 on Friday. Curis has a 12 month low of $1.02 and a 12 month high of $16.80. The company has a 50-day moving average price of $2.00 and a 200-day moving average price of $3.08. The stock has a market cap of $16.04 million, a price-to-earnings ratio of -0.24 and a beta of 3.65.

Institutional Investors Weigh In On Curis

A number of large investors have recently added to or reduced their stakes in CRIS. CM Management LLC lifted its stake in shares of Curis by 9.1% in the 1st quarter. CM Management LLC now owns 240,000 shares of the biotechnology company’s stock worth $504,000 after purchasing an additional 20,000 shares during the period. Wealthquest Corp purchased a new position in shares of Curis during the first quarter valued at about $1,542,000. XTX Topco Ltd purchased a new position in Curis during the 1st quarter valued at approximately $27,000. Squarepoint Ops LLC bought a new stake in Curis in the 4th quarter worth approximately $35,000. Finally, Millennium Management LLC raised its stake in Curis by 92.6% during the fourth quarter. Millennium Management LLC now owns 25,557 shares of the biotechnology company’s stock valued at $78,000 after purchasing an additional 12,287 shares in the last quarter. Institutional investors own 29.97% of the company’s stock.

Curis Company Profile

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.